Fate Therapeutics Inc (FATE) : Hochman Cole Investment Advisors reduced its stake in Fate Therapeutics Inc by 32.65% during the most recent quarter end. The investment management company now holds a total of 11,005 shares of Fate Therapeutics Inc which is valued at $18,598 after selling 5,336 shares in Fate Therapeutics Inc , the firm said in a disclosure report filed with the SEC on Jul 18, 2016.Fate Therapeutics Inc makes up approximately 0.01% of Hochman Cole Investment Advisors’s portfolio.
Other Hedge Funds, Including , First Manhattan Co boosted its stake in FATE in the latest quarter, The investment management firm added 3,750 additional shares and now holds a total of 7,750 shares of Fate Therapeutics Inc which is valued at $13,330.
Fate Therapeutics Inc opened for trading at $1.69 and hit $1.72 on the upside on Wednesday, eventually ending the session at $1.69, with a gain of 1.20% or 0.02 points. The heightened volatility saw the trading volume jump to 2,87,486 shares. Company has a market cap of $49 M.
Fate Therapeutics Inc. (Fate Therapeutics) is a clinical-stage biopharmaceutical company engaged in the development of programmed cellular therapeutics. The Company has a number of programmed cellular therapeutic candidates in development and research. The Company’s development programs include ProHema (FT1050-modulated hematopoietic cells within umbilical cord blood (UCB)) which targets Hematologic Malignancies and Inherited Metabolic Disorders therapeutic conditions and are in Phase II Phase Ib and Phase Ib respectively. Its development programs also include Programmed hematopoietic cells within mobilized peripheral blood (mPB) (FT1050+FT4145-modulated mPB) which is for Hematologic and Malignancies therapeutic area and is in IND enablement-stage. Its research programs include Programmed Hematopoietic Cells human induced pluripotent stem cells (hiPSC)-derived Hematopoietic Cells and hiPSC-derived Myogenic Progenitor Cells.